The Certified Methadone Advocate Course

Saturday, October 16, 2004 Preconference Events

Frederick W. Christie, MA

AFIRM

Long Island, New York
H. Westley Clark, MD, JD, MPH

CSAT

Rockville, MD
Stewart Leavitt, PHD

Addiction Treatment Forum

Glenview, IL
James P. Connolly, CMA

PA NAMA

Newtown, PA
Herman Joseph, PHD, CMA

NAMA

New York, NY
J. Thomas Payte, MD, CMA

Colonial Management Group

Orlando, FL
Walter Ginter, CMA

NAMA

Westport, CT
Thomas Kresina

NIDA/CSAT

Rockville, MD
Joycelyn Woods, MA, CMA

NAMA

New York, NY

It is the view of the National Alliance of Methafdone Advocates (NAMA) that everyone who supports the use of methadone treatment is a potential methadone advocate. We encourage all supporters of methadone treatment, patients and non-patient, to become Certified Methadone Advocates (CMAs) so that all the energies directed toward the advancement of methadone tratment produce positive results.

This course fulfills the training requirement for Certification as a Methadone Advocate. It is designed for non-clinicians and involves 8 hours of rigorius training. The course equips participants with the tools they will nedd to succeed in the strugle to have methadone maintenance treatment universally acceptied as the “gold standard” for addiction treatment.

With these goals in mind the course presetation is as follows:

  • Addiction and Methadone – scientifically accurate yet in language understandable to the non-clinician.
  • Regulation and Accreditation – explained by experts from the Center for Substance Abuse Treatment (CSAT) who understand the systemic complexities.
  • Methadone Mythology – exposing the myths surrounding methadone treatment.
  • The Certified Methadone Advocate (CMA) – the mechanism of certification and how it will professionalize those committed to advocacy, includes advocacy on the Net and Methadone Anonymous.
  • Methadone Stigma – a history of administrative and community prejudice directed at methadone patients, plus analyses of possible solutions.
  • Office-Based Treatment Model – whether buprenorphrine or methadone, an advance for patients and an administrative hurdle for implementation.
  • Hepatitis C – the second most important subject for all methadone patients.

Sponsored by the National Alliance of Methadone Advocates.

Supported by the National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment and Mallinckrodt, Inc.

Similar Posts